Clinical trial
Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer
NCT00186277 · Stanford University, Other · Completed
Key facts
| NCT number | NCT00186277 |
|---|---|
| Title | Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer |
| Official title | Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer |
| Lead sponsor | Stanford University, Other |
| Collaborators | Sanofi-Synthelabo Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer |
| Intervention type | Drug |
| Interventions | Oxaliplatin, Taxotere |
| Enrollment | 10 |
| Start date | Dec 1, 2003 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Sep 16, 2005 |
| Last update posted | Mar 30, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: